Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 8.71
SHWDY's Cash to Debt is ranked higher than
76% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SHWDY: 8.71 )
SHWDY' s 10-Year Cash to Debt Range
Min: 0.65   Max: No Debt
Current: 8.71

Equity to Asset 0.84
SHWDY's Equity to Asset is ranked higher than
90% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SHWDY: 0.84 )
SHWDY' s 10-Year Equity to Asset Range
Min: 0.62   Max: 0.84
Current: 0.84

0.62
0.84
Interest Coverage 71.57
SHWDY's Interest Coverage is ranked higher than
67% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. SHWDY: 71.57 )
SHWDY' s 10-Year Interest Coverage Range
Min: 16.51   Max: 480.94
Current: 71.57

16.51
480.94
F-Score: 4
Z-Score: 7.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.84
SHWDY's Operating margin (%) is ranked higher than
91% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. SHWDY: 20.84 )
SHWDY' s 10-Year Operating margin (%) Range
Min: 3.85   Max: 21.94
Current: 20.84

3.85
21.94
Net-margin (%) 14.53
SHWDY's Net-margin (%) is ranked higher than
87% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. SHWDY: 14.53 )
SHWDY' s 10-Year Net-margin (%) Range
Min: 1.1   Max: 23.63
Current: 14.53

1.1
23.63
ROE (%) 8.88
SHWDY's ROE (%) is ranked higher than
81% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SHWDY: 8.88 )
SHWDY' s 10-Year ROE (%) Range
Min: 0.75   Max: 15.78
Current: 8.88

0.75
15.78
ROA (%) 7.47
SHWDY's ROA (%) is ranked higher than
87% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. SHWDY: 7.47 )
SHWDY' s 10-Year ROA (%) Range
Min: 0.59   Max: 11.63
Current: 7.47

0.59
11.63
ROC (Joel Greenblatt) (%) 35.63
SHWDY's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. SHWDY: 35.63 )
SHWDY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.49   Max: 45.69
Current: 35.63

9.49
45.69
Revenue Growth (%) 0.90
SHWDY's Revenue Growth (%) is ranked higher than
63% of the 670 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SHWDY: 0.90 )
SHWDY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 13.5
Current: 0.9

0
13.5
EBITDA Growth (%) 12.60
SHWDY's EBITDA Growth (%) is ranked higher than
80% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SHWDY: 12.60 )
SHWDY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 38.2
Current: 12.6

0
38.2
EPS Growth (%) 27.80
SHWDY's EPS Growth (%) is ranked higher than
87% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. SHWDY: 27.80 )
SHWDY' s 10-Year EPS Growth (%) Range
Min: 0   Max: 103.5
Current: 27.8

0
103.5
» SHWDY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SHWDY Guru Trades in

SHWDY Guru Trades in

SHWDY Guru Trades in

Q3 2012

SHWDY Guru Trades in Q3 2012

Vanguard Health Care Fund 12,066,234 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SHWDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.40
SHWDY's P/E(ttm) is ranked higher than
90% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.90 vs. SHWDY: 19.40 )
SHWDY' s 10-Year P/E(ttm) Range
Min: 8.8   Max: 147.48
Current: 19.4

8.8
147.48
P/B 1.70
SHWDY's P/B is ranked higher than
86% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. SHWDY: 1.70 )
SHWDY' s 10-Year P/B Range
Min: 0.9   Max: 2.23
Current: 1.7

0.9
2.23
P/S 0.20
SHWDY's P/S is ranked higher than
76% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. SHWDY: 0.20 )
SHWDY' s 10-Year P/S Range
Min: 1.11   Max: 15.5
Current: 0.2

1.11
15.5
EV-to-EBIT 12.87
SHWDY's EV-to-EBIT is ranked higher than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. SHWDY: 12.87 )
SHWDY' s 10-Year EV-to-EBIT Range
Min: 6.4   Max: 79.7
Current: 12.87

6.4
79.7
PEG 7.46
SHWDY's PEG is ranked higher than
83% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 7.46 )
SHWDY' s 10-Year PEG Range
Min: 0.18   Max: 3.56
Current: 7.46

0.18
3.56
Shiller P/E 20.50
SHWDY's Shiller P/E is ranked higher than
90% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 121.61 vs. SHWDY: 20.50 )
SHWDY' s 10-Year Shiller P/E Range
Min: 10.63   Max: 21.18
Current: 20.5

10.63
21.18
Current Ratio 4.24
SHWDY's Current Ratio is ranked higher than
83% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. SHWDY: 4.24 )
SHWDY' s 10-Year Current Ratio Range
Min: 2.35   Max: 4.24
Current: 4.24

2.35
4.24
Quick Ratio 3.32
SHWDY's Quick Ratio is ranked higher than
82% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. SHWDY: 3.32 )
SHWDY' s 10-Year Quick Ratio Range
Min: 1.9   Max: 3.32
Current: 3.32

1.9
3.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
SHWDY's Dividend Yield is ranked higher than
75% of the 482 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. SHWDY: 2.20 )
SHWDY' s 10-Year Dividend Yield Range
Min: 0.75   Max: 4.12
Current: 2.2

0.75
4.12
Dividend growth (3y) 2.60
SHWDY's Dividend growth (3y) is ranked higher than
79% of the 351 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. SHWDY: 2.60 )
SHWDY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37
Current: 2.6

0
37
Yield on cost (5-Year) 2.56
SHWDY's Yield on cost (5-Year) is ranked higher than
77% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. SHWDY: 2.56 )
SHWDY' s 10-Year Yield on cost (5-Year) Range
Min: 0.87   Max: 4.8
Current: 2.56

0.87
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 33.41
SHWDY's Price/Net Current Asset Value is ranked higher than
51% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 33.41 )
SHWDY' s 10-Year Price/Net Current Asset Value Range
Min: 24.52   Max: 54.93
Current: 33.41

24.52
54.93
Price/Tangible Book 2.02
SHWDY's Price/Tangible Book is ranked higher than
87% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. SHWDY: 2.02 )
SHWDY' s 10-Year Price/Tangible Book Range
Min: 1.47   Max: 3.53
Current: 2.02

1.47
3.53
Price/DCF (Projected) 1.12
SHWDY's Price/DCF (Projected) is ranked higher than
94% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.36 vs. SHWDY: 1.12 )
SHWDY' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 1.13
Current: 1.12

0.62
1.13
Price/Median PS Value 1.28
SHWDY's Price/Median PS Value is ranked higher than
69% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. SHWDY: 1.28 )
SHWDY' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 6.39
Current: 1.28

0.57
6.39
Price/Peter Lynch Fair Value 3.48
SHWDY's Price/Peter Lynch Fair Value is ranked higher than
88% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SHWDY: 3.48 )
SHWDY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 3.07
Current: 3.48

0.4
3.07
Price/Graham Number 1.31
SHWDY's Price/Graham Number is ranked higher than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.09 vs. SHWDY: 1.31 )
SHWDY' s 10-Year Price/Graham Number Range
Min: 0.87   Max: 2.69
Current: 1.31

0.87
2.69
Earnings Yield (Greenblatt) 7.80
SHWDY's Earnings Yield (Greenblatt) is ranked higher than
88% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SHWDY: 7.80 )
SHWDY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 15.5
Current: 7.8

1.3
15.5
Forward Rate of Return (Yacktman) 8.98
SHWDY's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. SHWDY: 8.98 )
SHWDY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.6   Max: 85.4
Current: 8.98

9.6
85.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4507.Japan, SH0.Germany
Shionogi & Co., Ltd. develops, manufactures and markets pharmaceutical products for human and veterinary use. Its activities also include production of diagnostics and other related products.
» More Articles for OTCPK:SHWDY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Showa Denko Announces Recording Extraordinary Loss on Valuation of Investment Securities; Difference... Jul 31 2014
Showa Denko to Acquire Air Products' High-Purity Chlorine Business in Taiwan Jul 31 2014
Showa Denko Ups High-Purity Aluminum Foils Capacity in China Jul 25 2014
SDK Group Expanded Production Lines for LIB Packaging Laminates Jul 08 2014
Showa Denko Strengthens High-Purity Gas Supply System in Asia Jun 25 2014
SDK Group's Leading Edge Plant Factory Unit "SHIGYO(R) Unit" Adopted in a Large Plant Factory in... Jun 16 2014
Showa Denko Starts Up Ethyl Acetate Plant Using New Technology Jun 10 2014
Showa Denko (SDK) Acquisition of Vietnamese Aluminum Can Maker Completed Jun 02 2014
Showa Denko to Establish New Base for High-Purity N2O in South Korea Feb 26 2014
Showa Denko Ups High-Purity Ammonia Production Capacity in China Jan 31 2014
Showa Denko Group to Acquire Aluminum Can Maker in Vietnam Jan 08 2014
New Year's Message from Showa Denko CEO Ichikawa: Let's Strengthen Our Businesses to Return to a... Jan 06 2014
Showa Denko (SDK) Maps Out "PEGASUS Phase II" Business Plan Dec 13 2013
Showa Denko (SDK) Announces Changes in Corporate Management Dec 03 2013
Showa Denko Develops Dysprosium-free Magnetic Alloy for Factory Automation Applications Nov 25 2013
Showa Denko (SDK) Starts Shipments of 2.5-Inch 670 GB HD Media Nov 20 2013
Showa Denko and KH Neochem Agree to Dissolve Ethyl Acetate JV Nov 06 2013
Showa Denko to Launch 6" SiC Epitaxial Wafers for Power Devices Sep 29 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK